A wide armamentarium of small-molecule activators of the TP53 pathway, and an increasing understanding of molecular pathways triggered by mutant TP53 have accelerated efforts aimed at targeting TP53 function in AML. This evidence concerns the gene TP53 and acute myeloid leukemia.